In the present study, the effectiveness of a noncustom MAD was similar to that of a custom MAD in the treatment of patients with mild to severe OSA, The PSG outcomes did not differ significantly between the 2 devices, nor did the self-reported outcomes. These outcomes open the avenue to the possibility of using a noncustom MAD as a selection tool for MAD treatment eligibility to improve MAD treatment outcome. An advantage of using a noncustom MAD prior to a custom MAD is that therapy can be initiated directly. This allows the patient to experience the benefits and possible disadvantages of MAD therapy before a more expensive custom MAD is applied, thus providing an efficient and potentially cost-effective way of screening MAD treatment eligibility.
Comments